FDA Clears AI-Powered Module for Detecting Hemispheric Subdural Hematomas on CT
The Rapid SDH module on the RapidAI platform reportedly offers a sensitivity rate of 93 percent for detection of hemispheric subdural hematoma on non-contrast computed tomography (CT) scans.
The Food and Drug Administration (FDA) has granted 510(k) clearance for RapidAI’s Rapid SDH, an artificial intelligence (AI)-enabled module that reportedly notifies radiologists of suspected hemispheric subdural hematomas within one minute of reviewing a computed tomography (CT) scan.
For suspected acute and chronic hemispheric subdural hematomas > 1 mL, the Rapid SDH module offers a sensitivity rate of 93 percent and a specificity rate of 99 percent, according to RapidAI.
In addition to flagging suspected cases of hemispheric subdural hematomas, RapidAI said the Rapid SDH module facilitates multidisciplinary collaboration for the management of these patients via automated notification sent via the RapidAI app, PACS and e-mail.
"The FDA's clearance of Rapid SDH significantly enhances our expanding range of hemorrhagic and trauma care solutions at this crucial time of rapidly growing patient numbers, clinician shortages, and advancements in potential treatment options,” said Amit Phadnis, the chief innovation and technology officer of RapidAI. “Our goal is to continue to expand the capabilities and applications of our deep AI to deliver comprehensive clinical solutions that provide care teams with the crucial insights necessary to evaluate patients, streamline decision making, and expedite care for this common and dangerous disease.”
Recent Videos
Related Content
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Article
Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025Article
The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025Article
The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
